Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 May 2016

Fei Bing-Yuan, Wang Xiu-Ying, Fang Xue-Dong

Abstract excerpt

Colorectal cancer (CRC) global incidence is one of the highest among cancers. The KRAS gene has been shown as a robust biomarker for poor prognosis and drug resistance. MicroRNA-143 (miR-143) and let-7 are families of tumor suppressor microRNAs that are often downregulated in CRC, especially with coexistent KRAS mutations. In order to evaluate if miR-143 and/or let-7b replenishment would re-sensitize CRC cells to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genes, ras

Share to Neoplasm Proteins

Share to Oncogene Protein p21(ras)

Share to Paclitaxel

Source

Identifiers

PMID: 26581910
DOI: 10.1007/s13277-015-4354-6

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment.PMID 26581910Read ↗

Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143.Semantic proximity Read ↗

MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in gliomaSemantic proximity Read ↗

miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression.Semantic proximity Read ↗

Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview.Semantic proximity Read ↗

MicroRNA-143 Targets MACC1 to Inhibit Cell Invasion and Migration in Colorectal cancerSemantic proximity Read ↗

Restoring miR-145 overcome oxaliplatin resistance by targeting the ABCC1 gene and re-establishing drug-induced anti-cancer effects in colorectal cancerSemantic proximity Read ↗

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.Semantic proximity Read ↗

[miR-143 inhibits cell proliferation through targeted regulating the expression of K-ras gene in HeLa cells].Semantic proximity Read ↗

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.Semantic proximity Read ↗

Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.Semantic proximity Read ↗

Crocin Suppresses Colorectal Cancer Cell Proliferation by Regulating miR-143/145 and KRAS/RREB1 PathwaysSemantic proximity Read ↗

A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.